Nanobodies are single domain antibodies derived from mammals with heavy-chain antibodies that have unique properties such as nanoscale size, robust structure, stable and soluble behaviors in aqueous solution, reversible refolding of protein, high affinity and specificity for only one cognate target, and others. Nanobodies have a variety of applications, which range from basic science to clinical therapeutics. Due to their small size and single domain chain nanobodies have a larger binding surface and lower nonspecific background binding, and are used as affinity capture reagents. Furthermore, nanobodies can be used to treat cancer and other diseases by blocking ligand-receptor interactions, such as antagonizing the anti-von Willebrand factor to prevent thrombosis or inhibiting anti-TNF-α to treat arthritis. Nanobodies can also be expressed inside cells and fused with a fluorescent protein to monitor antigen activity. Nanobodies are well suited as protein stabilizers, which is particularly important during the crystallization of a protein. Thus, nanobodies are used in a number of protein crystallization studies due to their ability to lock proteins in a particular conformation, stabilize flexible domains. This increases the adoption of nanobodies and thereby, drives the growth of the nanobodies market. For instance, on October 2, 2017, the scientists at Aarhus University developed nanobodies. This provides a direct route for solving new X-ray crystal structures of protein complexes for understanding of cellular processes which is important for development of drugs.
Global Nanobodies Market - Impact of the Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic is expected to drive the growth of the global nanobodies market over the forecast period, owing to the inorganic activities by research institutes for developing treatments. For instance, in July 2021, DiosCURE Therapeutics SE , a manufacturer of immunotherapeutic has signed an exclusive licensing agreement with research and invention parties such as University Hospital Bonn, Macrostruct Holding & Consulting AB and Scripps Research a broad suite of intellectual property including DIOS203, DIOS202, and DIOS301 highly-effective therapy against SARS-CoV-2. This therapy is an option for urgent treatment for COVID-19 patients. These nanobody candidates are expected to be well-tolerated, highly efficacious, and cost-efficient in nanobody production with wide range of clinical applications.
DiosCURE Therapeutics SE, a manufacturer of immunotherapeutic treatments, has signed an exclusive licencing agreement with research and invention parties, the University of Bonn, University Hospital Bonn, Scripps Research, and Macrostruct Holding & Consulting AB, for a broad suite of intellectual property including DIOS-202, DIOS-203, and DIOS-301 highly-efficacious therapies against SARS-CoV-2.
Increasing research and development activities by market players owing to the prevalence of COVID-19 is expected to drive the global nanobodies market growth over the forecast period. For instance, on August 25, 2020, Novamab Biopharmaceuticals Co. Ltd, a manufacturer pharmaceutical products, has developed a new neutralizing nanobody, Nb11-59 as a potential inhaled therapy which helps in improving inhaling for COVID-19. Nb11-59 has highest neutralizing activity for which it was selected for further validation by interaction with receptor-binding domain (RBD) by structure prediction analysis.
The global nanobodies market is estimated to be valued at US$ 237.1 Mn in 2021 and is expected to exhibit a CAGR of 24.1% over the forecast period (2021-2028).
Figure 1: Global Nanobodies Market Share, (%), Analysis, By Product Type, 2021
Increasing research and development activities by the market players for developing treatment for diseases such as cancer, diabetes is expected to drive the growth of the global nanobodies market over the forecast period.
Market players are involved in research and development activities for developing treatment for diseases such as cancer, diabetes. This is expected to drive the growth of the market over the forecast period. For instance, on May 12, 2021 article published in Frontiers peer reviewed journal stated about molecular antibody called HER2 Nanobody which inhibits tumor proliferation in positive Breast cells in vitro and in vivo conditions which resulted as HER2 Nanobody restrained the cells proliferation and accelerate the cell apoptosis and it showed that proportion of cells in G1 phase increased where in S and G2 phase the proportion of cells got decreased after treating with HER2 nanobody cells stayed in resting state and few cells in mitotic phase.
Market players are indulged in receiving approvals from regulatory authorities, which is expected to drive the growth of the global nanobodies market over the forecast period.
Increasing approvals from regulatory authorities is expected to drive the growth of the global nanobodies market over the forecast period. For instance, in March 2021, Taisho Pharmaceutical Co., Ltd. , a pharmaceutical manufacturer of analgesics , has submitted an application of approval for manufacturing and market the anti-TNFα NANOBODY therapeutic licensed from Ablynx, a subsidiary of Sanofi S.A. in 2015, and developed by Taisho Pharmaceutical Co., Ltd., in Japan, submitted to the Ministry of Health, Labour and Welfare of Japan for the indication of rheumatoid arthritis (RA).
|Base Year:||2020||Market Size in 2021:||
US$ 237.1 Mn
|Historical Data for:||2018 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||24.1%||2028 Value Projection:||
US$ 1,074.1 Mn
Merck KGaA, Sanofi (Ablynx), Alphamab Oncology, Novartis AG, Genscript, Taisho Pharmaceutical Holdings Co., Ltd., Sensei Biotherapeutics, Inc., Cusabio Technology LLC., ChromoTek GmbH, Beroni Group, ExeVir Bio BV, Absolute Antibody, Alpalife (Shenzhen kangti Co., Ltd.), DiosCURE Therapeutics SE, Thermo Fisher Scientific Inc., PerkinElmer Inc. (BioLegend, Inc.), and Abnova Corporation
|Restraints & Challenges:||
Global Nanobodies Market – Restraints
Nanobodies are increasingly becoming popular in research, diagnostic, and therapeutic use. However, high production cost and limitations for production are likely to hamper the growth of the global nanobodies market. For instance, in November 2021, center for molecular medicine, U.S. producing nanobodies US$ 9,000 and in another instance where monoclonal and polyclonal antibodies are slightly safer to produce than nanobodies, as there are various biohazards molecules involved in nanobody production. The biohazards result mainly from use of hazardous bacteriophages for selection of nanobodies. The heavy chain antibodies from which nanobodies are developed can only be obtained from camelids and sharks. Traditional monoclonal antibodies, on the other hand, are obtained from mice. Hence, the development of nanobodies require larger, more complicated animal husbandry for obtaining the desired antibody. The following flowchart is indicating the single variable domain on heavy chain (VHH) recombinant antibody production from camelid.
Global Nanobodies Market – Regional Analysis
On the basis of region, the global nanobodies market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America nanobodies market is expected to hold a dominant position during the forecast period, owing to the inorganic activities such as collaborations and partnerships. For instance, on April 29, 2021, Alphamab Oncology which is a developer and manufacturer of innovative therapeutic drugs for cancer treatment announced that it entered into a clinical trial collaboration and supply agreement with Pfizer Inc., to evaluate the efficacy and safety of KN046 which is recombinant humanized bispecific antibody is combine with Inlyta (axitinib) for the first-line treatment of non-small cell lung cancer (NSCLC).
Furthermore, Europe is expected to witness significant growth in the nanobodies market, owing to the increasing focus on developing nanobodies to strengthen the therapeutic use. For instance, on July 28, 2021, the Göttingen researchers engaged in preparing the nanobodies for therapeutic use and was supported by Max-Planck-Innovation GmbH, Lead Discovery Center GmbH and Holm Keller GmBH Foundation. They developed mini-antibodies that block the SARS-COV-2 and its new variants.
Figure 2: Global Nanobodies Market (US$ Mn), by Region, 2021
Global Nanobodies Market – Competitive Landscape
Major players operating in the global nanobodies market include Merck KGaA, Sanofi (Ablynx), Alphamab Oncology, Novartis AG, Genscript, Taisho Pharmaceutical Holdings Co., Ltd., Sensei Biotherapeutics, Inc., Cusabio Technology LLC., ChromoTek GmbH, Beroni Group, ExeVir Bio BV, Absolute Antibody, Alpalife (Shenzhen kangti Co., Ltd.), DiosCURE Therapeutics SE, Thermo Fisher Scientific Inc., PerkinElmer, Inc. (BioLegend, Inc.), and Abnova Corporation.
Nanobodies are engineered antibodies that have a single domain developed by heavy chains with antigen–binding. These antibodies can be engineered and are suitable for various applications for research, therapeutic development, and medical diagnosis due to their size and single-chain nature. Nanobodies have various interesting applications including research on clinical therapeutics. Nanobodies are extensively used in the field of diagnosis and research, and it plays a crucial role and has great potential in noninvasive in vivo imaging. Nanobodies meet requirements to become a generic imaging tracer and offer benefits in molecular imaging, which leads to an increase in the use of nanobodies.
Market players are indulged in research and development activities for advancement of nanobodies for therapeutical treatments, which is expected to drive the growth of the global nanobodies market over the forecast period. For instance, according to an article published on Nature Journal on December 21, 2020, researchers at National Institutes of Health isolated a set of nanobodies against SARS-CoV-2. This nanobody is called NIH-CoVnb-112, which binds and blocks the variant form of SARS-Cov-2 spike protein.
Increasing awareness about early diagnosis as well as treatment is expected to drive the growth of the global nanobodies market over the forecast period. For instance, in October 2020, the Government Royapettah Hospital (GRH) organized an awareness program on breast cancer in India. This enabled to increase early detection, diagnosis, and availability of advanced technologies to improve survival rate of patients. This program aimed to create awareness about breast cancer and prevention at an early stage through early detection to avoid further consequences. By using nanobodies, which work as substitutes for naturally occurring antibodies for cancer treatment, they bind to the antigens on the surface of cancer cells, which helps to detect the cancer cells and block their growth. This can help in reducing the prevalence of cancer.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.